Research & Development
The Didiall, Inc. company has developed new innovative anticoagulant drug on its own cost during last year. The results of these activities are as follows:
- Target protein has been selected. This protein is a target for next-generation anticoagulants.
- The company has bought necessary equipment and reagents to measure biological activity of chemical compounds and potential anticoagulants «in vitro» and its specialists have acquired a skills of measuring procedures.
- The synthesis scheme has been determined considering its cost and practicability for certain protein and potential drug. Numerical calculations have been done based on that scheme.
- New class of patent-clear chemical compounds, i.e. potential anticoagulant drugs has been developed.
- The Company has developed method of potential anticoagulant drug synthesis.
- Some compounds from potential anticoagulants drug class have been synthesized.
- Biological activity of synthesized potential anticoagulant drugs has been measured «in vitro». Activity was found to be equal 0.095nM for compound DD175, fig. 1. It is like up-to-date substances, potential anticoagulant drug of next generation.
- Biological activity of compound DD175 has been measured for human blood. Activity was found to be equal PT2 = 3 mkM for compound DD175. It is like up-to-date substances, potential anticoagulant drug of next generation.
- Acute toxicity has been detected for DD175 on rats. It appeared to be enough for further development of the compound as a medicine. Lethal doze for rats was LD50>100 mg per kilo of live weight.
- At the moment the company is preparing to experiments on animals and caring out negotiations with organizations that perform clinical testing.
Fig. 1. Biological activity of compound DD175 developed by Didiall, Inc. «in vitro».